Treatment of High-Risk Neuroblastoma

被引：7
|
作者：
Krystal, Julie [1 ]
Foster, Jennifer H. [2 ]
机构：
[1] Cohen Childrens Med Ctr, Zucker Hofstra Sch Med, Dept Pediat, New Hyde Pk, NY 11040 USA
[2] Texas Childrens Canc Ctr, Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA
来源：
CHILDREN-BASEL | 2023年 / 10卷 / 08期
关键词：
neuroblastoma; pediatric oncology; solid tumor; OPEN-LABEL; CLASSIFICATION-SYSTEM; PROGNOSTIC IMPACT; CHILDHOOD-CANCER; FREE SURVIVAL; LOCAL-CONTROL; COG A3973; PHASE-II; CHILDREN; CHEMOTHERAPY;
D O I：
10.3390/children10081302
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
High-risk neuroblastoma is a highly aggressive solid tumor that most commonly presents in early childhood. Advances in treatment through decades of clinical trials and research have led to improved outcomes. This review provides an overview of the current state of treatment for high-risk neuroblastoma.
引用
收藏
页数：11
相关论文
共 50 条
  • [1] Treatment of High-Risk Neuroblastoma
    Hizhnikov, A.
    Kazancev, A.
    Kerimov, P.
    Pimenov, R.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S447 - S447
  • [2] Treatment of High-Risk Neuroblastoma
    Sung, Kiwoong
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S3 - S3
  • [3] High-Risk Neuroblastoma Treatment Review
    Smith, Valeria
    Foster, Jennifer
    CHILDREN-BASEL, 2018, 5 (09):
  • [4] Eflornithine for treatment of high-risk neuroblastoma
    Jiang, Jianxiong
    Yu, Ying
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2024, 45 (06) : 577 - 578
  • [5] Rethinking high-risk neuroblastoma treatment
    Cohn, Susan L.
    Pearson, Andrew D. J.
    PEDIATRIC BLOOD & CANCER, 2022, 69 (08)
  • [6] Identifying treatment response in high-risk Neuroblastoma
    Roels, F.
    Hero, B.
    Oberthuer, A.
    Berthold, F.
    Fisher, M.
    KLINISCHE PADIATRIE, 2011, 223 (03): : 197 - 197
  • [7] New Therapeutic Targets for the Treatment of High-Risk Neuroblastoma
    Wagner, Lars M.
    Danks, Mary K.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2009, 107 (01) : 46 - 57
  • [8] Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma
    Mora, Jaume
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (05) : 647 - 653
  • [9] Chemoimmunotherapy for high-risk neuroblastoma
    Kushner, Brian H.
    LANCET ONCOLOGY, 2017, 18 (07): : 845 - 846
  • [10] Induction for high-risk neuroblastoma
    Kushner, Brian H.
    Cheung, Nai-Kong V.
    PEDIATRIC BLOOD & CANCER, 2007, 49 (03) : 221 - 223
12345